CHICAGO--(BUSINESS WIRE)--A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, will present updates on three ...
AGOURA HILLS, Calif.--(BUSINESS WIRE)--A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, today announced ...
First complete response to a CAR T-cell therapy reported in a non-small cell lung cancer patient; the patient had high-risk genetic mutations and was refractory to first-line therapy A2B694 has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results